- Neoadjuvant therapy impact in early pancreatic cancer: “bioborderline” vs. “non-bioborderline”
-
Taboada AGM, Lominchar PL, Martínez MF, García-Alfonso P, Martin AM, Asencio JM
- KMID: 2536387
- Ann Hepatobiliary Pancreat Surg.
- 2022 Nov;26(4):363-374.
- doi: 10.14701/ahbps.22-023
Backgrounds/Aims: To analyze the results of the neoadjuvant treatment of patients in our center with early pancreatic cancer. Methods: Eighty-four patients with early pancreatic cancer (I–II) were included, of which 59... -
- CITED
-
- Close
- SHARE
-
- Close
- Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades
-
Taboada AGM, Lominchar PL, Roman LM, García-Alfonso P, Martin AJM, Rodriguez JAB, Pascual JMA
- KMID: 2516238
- Ann Hepatobiliary Pancreat Surg.
- 2021 May;25(2):179-191.
- doi: 10.14701/ahbps.2021.25.2.179
In the last two decades, pancreatic cancer has been undergoing important changes in its perioperative management due to the great interest in multidisciplinary management and preoperative multimodal therapy, which in... -
- CITED
-
- Close
- SHARE
-
- Close
